Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXY34J)

• Drug Name: S-110 Drug Info
• Synonyms: DNA demethylating agent (myelodysplastic syndrome), Supergen

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 3	[1]
Chronic myelogenous leukaemia	2A20.0	Phase 3	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]

• Cross-matching ID:
  PubChem CID: 137699198
  TTD Drug ID: DMXY34J

Molecule-Related Drug Atlas

Drug(s) Targeting DNA [cytosine-5]-methyltransferase 1 (DNMT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CC-486	DMTNQB0	Acute myeloid leukaemia	2A60	Phase 3	[5]
SGI110	DM1NQDW	Acute myeloid leukaemia	2A60	Phase 3	[6]
Guadecitabine	DM9Y3EG	Myelodysplastic syndrome	2A37	Phase 3	[2]
Palifosfamide	DMMIYZ7	Soft tissue sarcoma	2B57	Phase 2	[7]
RX-3117	DME8ARP	Bladder cancer	2C94	Phase 2	[8]
Antroquinonol	DMRGQVZ	Non-small-cell lung cancer	2C25.Y	Phase 2	[9]
GSK4172239	DM930LE	Sickle-cell disorder	3A51	Phase 1	[10]
PMID27376512-Compound-MTC-424	DMGNRZU	N. A.	N. A.	Patented	[11]
PMID27376512-Compound-MTC-427	DMWXEZD	N. A.	N. A.	Patented	[11]
PMID27376512-Compound-MTC-422	DM1MVQD	N. A.	N. A.	Patented	[11]

Drug(s) Targeting DNA [cytosine-5]-methyltransferase (DNMT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[12]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[13]
ASTX727	DM4HK8Z	Chronic myelogenous leukaemia	2A20.0	Phase 3	[2]
PMID27376512-Compound-PG-11047	DM5K4YF	N. A.	N. A.	Patented	[11]
PMID27376512-Compound-PG-11048	DM3U7RN	N. A.	N. A.	Patented	[11]
PMID27376512-Compound-MTC-434	DM70CTE	N. A.	N. A.	Patented	[11]
PMID27376512-Compound-CROs	DMBFUTL	N. A.	N. A.	Patented	[11]
(L-)-S-adenosyl-L-homocysteine	DMDUN83	Discovery agent	N.A.	Investigative	[14]
NSC-622445	DME35CB	Discovery agent	N.A.	Investigative	[13]
NSC-622444	DMM5UT9	Discovery agent	N.A.	Investigative	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA [cytosine-5]-methyltransferase (DNMT)	TTHVCUP	NOUNIPROTAC	Inhibitor	[3]
DNA [cytosine-5]-methyltransferase 1 (DNMT1)	TT6S2FE	DNMT1_HUMAN	Inhibitor	[4]

References

• [1] ClinicalTrials.gov (NCT02348489) SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther. 2010 May;9(5):1443-50.
• [5] Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 2016 Apr;30(4):889-96.
• [6] Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015;10(3):237-46.
• [7] Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs. 2012 Feb;23(2):173-84.
• [8] Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360). Invest New Drugs. 2013 Dec;31(6):1444-57.
• [9] Antroquinonol D, isolated from Antrodia camphorata, with DNA demethylation and anticancer potential. J Agric Food Chem. 2014 Jun 18;62(24):5625-35.
• [10] Clinical pipeline report, company report or official report of GlaxoSmithKline
• [11] DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
• [12] The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid l... Leukemia. 2009 Jun;23(6):1019-28.
• [13] Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
• [14] Constrained (l-)-S-adenosyl-l-homocysteine (SAH) analogues as DNA methyltransferase inhibitors. Bioorg Med Chem Lett. 2009 May 15;19(10):2742-6.